ABSTRACT

Background and Objectives: To present the methods and outcomes of total laparoscopic hysterectomy with debulking surgery for large cervical fibroids.

Methods: This is a single-center study. Twenty-one women who underwent total laparoscopic hysterectomy between October 1, 2012 and November 30, 2020 for large cervical fibroids (diameter ≥10 cm) based on a diagnosis by magnetic resonance imaging were enrolled. Conventional total laparoscopic hysterectomy for large cervical fibroids was initially attempted. If this could not be completed, debulking surgery, such as enucleation of large cervical fibroids or cervical amputation, was performed during total laparoscopic hysterectomy.

Results: Total laparoscopic hysterectomy could be completed in all 21 patients with large cervical fibroids without blood transfusion. Conventional total laparoscopic hysterectomy was performed in four patients (19%), and 17 patients (81%) required debulking surgery at the time of total laparoscopic hysterectomy. The median diameter of the major axis of the cervical fibroid, uterine weight, intraoperative blood loss, and operative time were 12 cm, 750 g, 100 mL, and 191 min, respectively.

Conclusion: Total laparoscopic hysterectomy for large cervical fibroids, although minimally invasive, requires a high level of laparoscopic skill. However, our data suggests that total laparoscopic hysterectomy for large cervical fibroids can be feasible, with an acceptable level of blood loss, by performing debulking surgeries such as enucleation of large cervical fibroids or cervical amputation.

Key Words: Cervical amputation, Cervical fibroid, Debunking surgery, Enucleation, Total laparoscopic hysterectomy.

INTRODUCTION

Uterine cervical fibroids account for 1 – 2% of all uterine fibroids1,2 and large cervical fibroids (≥ 10 cm) are even rarer. Total laparoscopic hysterectomy (TLH) for large cervical fibroids is difficult as their presence in the pelvic cavity leads to poor pelvic visibility, decreased uterine mobility, deformity and dislocation of the uterine cervix, and displacement of the bladder and ureter from their anatomical positions. Since the uterine cervix has abundant blood vessels, including the uterine artery and vein, TLH for large cervical fibroids often results in substantial blood loss. Therefore, total abdominal hysterectomy (TAH) is often performed in such cases.3,4 However, compared with TAH, TLH has many advantages, such as better cosmetic outcome, less blood loss, less postoperative pain, shorter hospitalization period, and shorter recovery time.5,6 Furthermore, there are only a few reports of laparoscopically assisted vaginal hysterectomy (LAVH) or TLH for cervical fibroids,7,8 and they were performed using temporary endovascular balloon occlusion of the bilateral internal iliac arteries,7 and ureterolysis, transection of the anterior layer of the vesicouterine ligament, and isolation of the ureter.8 These methods require special instruments or special surgical techniques that are not generally performed for removal of the uterus or uterine fibroids.

Laparoscopic myomectomy (LM) during laparoscopic hysterectomy for large uterine fibroids has been reported to be an effective technique.9 Enucleation of cervical fibroids during TAH has also been reported,5,4 and some studies have reported LM for cervical fibroids.10-12 Furthermore, laparoscopic supracervical amputation during LAVH for a large myomatous uterus has been reported to be effective.13,14 These reports indicate the possibility of successfully performing an otherwise difficult TLH for large cervical fibroids.
by performing debulking surgery, such as enucleation of large cervical fibroids or cervical amputation. Enucleation and cervical amputation are generally performed as laparoscopic surgery of uterine fibroids.9–14 Therefore, if TLH for large cervical fibroids (≥ 10 cm) can be performed with debulking surgery, the method will provide a minimally invasive and relatively easier alternative to using special instruments or special surgical techniques (as previously described). Thus, this study aimed to report the methods and outcomes of TLH for large cervical fibroids by performing debulking surgery through a consecutive case series.

**MATERIALS and METHODS**

**Patients and Study Design**

We enrolled 21 patients with large cervical fibroids who underwent TLH between October 1, 2012 and November 30, 2020. The patients were diagnosed with large cervical fibroids (diameter ≥ 10 cm) by magnetic resonance imaging (MRI). The indications for TLH included menorrhagia, anemia, dysmenorrhea, abdominal pressure, chronic pelvic pain, frequent urination, and urinary retention. Pelvic examinations and pre-operative examinations, including transvaginal and/or abdominal ultrasound examinations, uterine cervical cytology, endometrial cytology at the time of atypical genital bleeding, and MRI were performed. One or two radiologists used MRI to assess the condition of the entire uterus, the status of the uterine fibroids, the presence or absence of malignant tumors, ovarian disease, and deep infiltrating endometriosis (Figures 1A, 2A, 3A). Women with suspected malignant findings based on these examinations were excluded from this study. Classification of large cervical fibroids in relation to the uterine myometrium was performed using the leiomyoma subclassification system of the Federation Internationale de Gynecologie et d’Obstetrique.15

---

**Figure 1.** Conventional total laparoscopic hysterectomy (case 13). **A:** Sagittal magnetic resonance image. A large cervical fibroid was recognized. **B:** Status of the large cervical fibroid under laparoscopy. **C:** Dissection of the peritoneum of the left vesicouterine pouch. **D:** The left uterine blood vessels and cervical fibroid. CF, cervical fibroid. UV, uterine vessel.
Gonadotropin-releasing hormone (GnRH) agonist (1.88 mg of leuprolide acetate, monthly injection; Takeda Pharmaceutical Co., Tokyo, Japan) or GnRH antagonist (40 mg of relugolix, oral, once daily) (ASKA Pharmaceutical Co., Tokyo, Japan) was administered for 1 to 6 months to reduce uterine volume. All patients provided informed consent for the surgical procedures and the use of their clinical information for research purposes. This study was reviewed and approved by the Institutional Review Board. All patients were followed-up for at least 4 months after surgery.

Conventional TLH (TLH without Debulking Surgery)

Conventional TLH was performed in the standardized manner using three trocars; a 10-mm trocar was placed through the umbilicus and two 5-mm trocars were inserted in the lower abdomen (1 trocar on each side) and shifted upward according to the position of the uterine fundus to obtain good visibility. Carbon dioxide was used to establish pneumoperitoneum, with the abdominal pressure set to 8 mmHg. The pelvis was inspected under laparoscopic guidance (Figures 1B, 2B, 3B). At the beginning of the TLH, a diluted vasopressin solution (15 – 20 mL; 20 U in 50 mL of saline) was injected16,17 at two to three locations into the myometrium around the uterine fibroid to decrease blood loss. The plunger of the syringe was withdrawn prior to injection to prevent inadvertent injection of vasopressin into the blood vessels. The diluted vasopressin solution was administered once every 40 – 50 minutes until the uterine blood vessels were cauterized and cut. The round ligaments, fallopian tubes, and ovarian or infundibulopelvic ligaments were cauterized and...
Figure 3. Cervical amputation with enucleation of large cervical fibroid during total laparoscopic hysterectomy (case 8). A: Sagittal magnetic resonance image. A large cervical fibroid was found in the posterior cervix. B: Status of the large cervical fibroid at laparoscopy. C: Dissection of the bladder from the anterior uterine cervix. D: Cauterization and cutting of right uterine blood vessels. E: Cervical amputation with an ultrasonic scalpel. F: Enucleation of the posterior large cervical fibroid after cervical amputation. G: Residual uterine cervix. Good pelvic visibility and good cervical mobility. H: Detachment of the bladder from the anterior residual uterine cervix. I: Cauterization of left uterine blood vessels of residual uterine cervix. J: Illustration showing detachment of the bladder from the anterior uterine cervix: (1) amputation of the uterine cervix (2), and enucleation of the large cervical fibroid (3) during total laparoscopic hysterectomy. B, bladder; CF, cervical fibroid; U, uterus; UC, uterine cervix; UV, uterine vessel.
The peritoneum of the broad ligament and the vesicouterine pouch were cut (Figure 1C), and the bladder was bluntly detached from the anterior uterine cervical wall (Figure 3C). After detaching the crude connective tissue from the uterine blood vessels (Figure 1D), the uterine blood vessels were cauterized and cut. The uterine manipulator was removed, and a cylindrical vaginal pipe was inserted. Circumferential colpotomy was performed and the uterus was morcellated vaginally. From November 1, 2018 onwards, an in-bag manual extraction of the uterus was performed vaginally, to prevent the spreading of occult uterine malignancy tissue. The vaginal stump was sutured in two layers with absorbable suture. Cystoscopy with intravenous indigo carmine was performed using a 5-mm laparoscope in order to detect lower urinary tract injuries. The skin incisions were closed, and all extracted tissues were examined histopathologically.

Enucleation of Large Cervical Fibroids during TLH

After inspection of the status of the uterus and the large cervical fibroid (Figure 2B), ligaments and vessels around the uterus were cauterized and cut in order to minimize blood loss before performing the enucleation of the cervical fibroid. The myometrium was incised, and the cervical fibroid was enucleated (Figures 2C, 2D). The enucleated wound was sutured to prevent bleeding (Figure 2E). Pelvic visibility and uterine mobility were improved following enucleation (Figure 2F). After detaching the uterus from the vaginal wall, the uterus and the enucleated fibroid were connected with sutures (Figure 2G), morcellated vaginally, and extracted.

Cervical Amputation with or without Enucleation of Large Cervical Fibroids during TLH

The surgical procedure is similar to conventional TLH up to the point of cauterization and cutting of the uterine blood vessels. After the uterine blood vessels were cauterized and cut (Figure 3D), cervical amputation was performed with an ultrasonic scalpel (Figure 3E). If the large cervical fibroid was found attached to the lower uterine cervix even after the cervical amputation, the fibroid was enucleated (Figure 3F). The lower uterine cervix then remained, and good pelvic visibility and good uterine cervical mobility were obtained (Figure 3G). Tracheectomy of the residual cervix was performed laparoscopically (Figures 3H, 3I). Subsequently, the amputated uterus and fibroid were morcellated and extracted transvaginally. Figure 3J shows this procedure.

Selection of Operative Methods (Figure 4)

Conventional TLH for large cervical fibroids was attempted initially. When it could not be completed, enucleation of the large cervical fibroid was attempted. When conventional TLH...
could not be performed even after enucleation or enucleation of the large cervical fibroid could not be performed, cervical amputation alone or cervical amputation with enucleation of the large cervical fibroid was attempted. When feasible, trachelectomy was performed laparoscopically. When these methods could not be performed, TAH was attempted.

Complications

Complications were classified according to the Clavien-Dindo classification.20

Statistical Analyses

Data are expressed as the median value and range (minimum–maximum). All statistical analyses were performed using Microsoft 365 Excel for Mac OS X (Microsoft, Redmond, WA).

RESULTS

Of the 463 patients who underwent TLH during this study period, 21 (4.5%) had large cervical fibroids (diameter ≥ 10 cm) and were included in this study. The clinical characteristics of the patients are shown in Table 1. Nine patients (42.9%) were nulliparous, six patients had a history of pelvic surgery (28.6%), and one patient had a history of uterine artery embolization (4.8%).

The median value of the major axis of the cervical fibroids was 12 cm (range, 10 – 16 cm). The median number of fibroids larger than 2 cm (including the large cervical fibroid) was two. There were no cases of suspected malignancy during the pre-operative examinations. Fourteen of the 21 patients (66.7%) received the GnRH agonist or antagonist. However, seven patients (33.3%) underwent TLH without GnRH agonist or antagonist; three of these patients required early surgery due to repeated urinary retention requiring urethral catheterization, and four refused the GnRH agonist or antagonist due to the side effects or cost.

Table 2 shows the surgical outcomes. Conventional TLH was performed in four women (19.0%), enucleation of a large cervical fibroid during TLH was performed in 10 women (47.6%), cervical amputation during TLH was performed in 10 women (47.6%) and both enucleation of a large cervical fibroid and cervical amputation were performed in three women (14.3%). There were no cases of cervical fibroids that could be enucleated transvaginally before performing a TLH (type 0 or 1 according to the leiomyoma subclassification system).15 All cases with a history of cesarean section had adhesions between the bladder and anterior uterine cervix. In two cases, endometriosis was recognized. One of them had an obliterated Douglas pouch and severe adhesions around the uterus due to severe endometriosis as well as a history of abdominal myomectomy and cesarean section. An ovarian cyst was noted in one case.

The median uterine weight, intraoperative blood loss, operative time (defined as the time from skin incision to closure), and postoperative hospitalization were 750 g (range, 318 – 1502 g), 100 mL (range, 10 – 675 mL), 191 min (range, 147 – 254 min), and 4 days (range, 4 – 6 days), respectively. Histopathological examination did not reveal malignancies. The histopathologic findings of the large cervical fibroid are presented in Table 2. Intraoperative complications occurred in one case (case 17), resulting from cauterization of the ureter. Therefore, a ureteral catheter was placed in the ureter by a urologist during TLH, and the patient was discharged from the hospital 5 days after surgery with the ureteral catheter. An ileal conduit urinary diversion was performed 12 months after the initial surgery (Clavien–Dindo grade 3). Clavien–Dindo grade ≥ 2 complications were not seen, except in this patient.

DISCUSSION

In this study, TLH were successfully completed by performing debulking surgery and without the need for blood transfusion in 21 patients with large cervical fibroids. The reason for performing debulking surgery during such TLH was to improve the pelvic cavity visibility and uterine mobility. Furthermore, performing of debulking surgery allows the bladder and ureters to revert to their anatomical positions, along with the displaced and/or deformed uterine cervix that also return to its anatomical position and shape. In terms of debulking surgery, enucleation of large cervical fibroids or cervical amputation were performed. It has been previously reported that LM for cervical fibroids caused a median blood loss between 50 and 105 mL, with a maximum of 500 mL.10–12 Therefore, blood loss during LM for cervical fibroids is not always excessive. Concerning cervical amputation during LAVH, Yen et al. reported that laparoscopic bipolar uterine vascular coagulation and supracervical amputation significantly reduced the operative time and blood loss in LAVH of the uterus over 12 weeks.14 In this study, all cases in which conventional TLH or enucleation of a large cervical fibroid during TLH could not be performed, were finally completed via TLH by performing cervical amputation. This suggests the effectiveness of cervical amputation. Therefore, when
| Case | Age (Years) | BMI | Obstetric History | Main Symptoms, except for urinary symptoms | Main Urinary Symptoms | Previous Pelvic Surgery | Cervical Fibroid Size (cm) | PALM-COEIN Classification of cervical fibroid | Median Number of fibroids larger than 2 cm | GnRHa Administration (No. of Months) |
|------|-------------|-----|-------------------|---------------------------------------------|-----------------------|-------------------------|---------------------------|--------------------------------------------|------------------------------------------|------------------------------------------|
| 1    | 48          | 21  | 0G                | Abdominal pressure                          | No                    | No                      | 11 × 10 × 9                | Types 2 – 5                                | 5                                        | 4                                        |
| 2    | 46          | 17  | 4G3P              | Menorrhagia, abdominal pressure             | Frequent urination, urinary retention, residual urine | No                      | 12 × 9 × 8                 | Types 2 – 5                                | 1                                        | 0                                        |
| 3    | 42          | 19  | 2G1P1C            | Menorrhagia, dysmenorrhea, abdominal pain    | No                    | Abdominal myomectomy once, cesarean delivery, once | 14 × 12 × 9                | Types 2 – 5                                | 2                                        | 3                                        |
| 4    | 40          | 22  | 7G3P              | Abdominal pressure                          | Residual urine        | No                      | 12 × 10 × 9                | Types 2 – 5                                | 6                                        | 3                                        |
| 5    | 44          | 25  | 0G                | Menorrhagia, dysmenorrhea, abdominal pressure | Frequent urination     | No                      | 16 × 13 × 10               | Types 2 – 5                                | 3                                        | 3                                        |
| 6    | 51          | 22  | 3G0P              | Abdominal pressure                          | Frequent urination     | No                      | 16 × 14 × 10               | Type 6                                     | 2                                        | 3                                        |
| 7    | 44          | 23  | 1G1P              | Menorrhagia, dysmenorrhea, abdominal pressure | Frequent urination     | No                      | 12 × 10 × 9                | Types 2 – 5                                | 6                                        | 4                                        |
| 8    | 45          | 29  | 0G                | Menorrhagia                                 | No                    | Laparoscopic myomectomy once | 14 × 11 × 9                | Types 6                                     | 6                                        | 4                                        |
| 9    | 37          | 23  | 2G2P2C            | Menorrhagia, dysmenorrhea                   | No                    | Cesarean delivery, twice | 11 × 11 × 9                | Types 2 – 5                                | 1                                        | 6                                        |
| 10   | 48          | 21  | 3G2P              | Menorrhagia, abdominal pressure             | Frequent urination, urinary retention  | No                      | 11 × 11 × 9                | Types 2 – 5                                | 1                                        | 0                                        |
| 11   | 52          | 27  | 2G2P              | Menorrhagia, dysmenorrhea, abdominal pressure | No                    | No                      | 14 × 12 × 9                | Types 2 – 5                                | 1                                        | 6                                        |
| 12   | 54          | 21  | 2G0P              | Dysmenorrhea, abdominal pressure            | Frequent urination, urinary retention, residual urine | No                      | 12 × 11 × 10               | Types 2 – 5                                | 1                                        | 2                                        |
| Case | Age (Years) | BMI | Obstetric History | Main Symptoms, except for urinary symptoms | Main Urinary Symptoms | Previous Pelvic Surgery | Cervical Fibroid Size (cm) | PALM-COEIN Classification of cervical fibroid | Median Number of fibroids larger than 2 cm | GnRHa Administration (No. of Months) |
|------|-------------|-----|-------------------|------------------------------------------|----------------------|------------------------|---------------------------|-----------------------------------------------|------------------------------------------|-------------------------------|
| 13   | 46          | 21  | 3G2P              | Menorrhagia, abdominal pressure, abdominal pain | Frequent urination, urinary retention | Appendectomy          | 11 × 9 × 8                | Types 2 – 5                                      | 1                                           | 0                             |
| 14   | 43          | 18  | 0G                | Menorrhagia, abdominal pressure            | Frequent urination, urinary retention | No                    | 16 × 12 × 11               | Types 2 – 5                                      | 2                                           | 5                             |
| 15   | 65          | 23.7| 2G2P2C            | Abdominal pressure, abdominal pain         | No                    | Cesarean delivery, twice | 12 × 9 × 10               | Types 2 – 5                                      | 1                                           | 0                             |
| 16   | 46          | 28  | 0G                | Dysmenorrhea, abdominal pressure           | No                    | No                    | 11 × 10 × 9                | Types 2 – 5                                      | 6                                           | 5                             |
| 17   | 45          | 17  | 2G2P              | Abdominal pressure                         | No                    | No                    | 11 × 10 × 8                | Types 2 – 5                                      | 1                                           | 0                             |
| 18   | 51          | 17  | 1G1P              | Menorrhagia, anemia, abdominal pressure     | No                    | Appendectomy          | 12 × 11 × 10               | Type 6                                          | 7                                           | 4                             |
| 19   | 54          | 30  | 2G2P              | Menorrhagia, anemia                        | No                    | No                    | 10 × 9 × 7                 | Types 2 – 5                                      | 3                                           | 0                             |
| 20   | 45          | 21  | 0G                | Dysmenorrhea, abdominal pressure           | No                    | Uterine artery embolization | 12 × 8 × 11               | Types 2 – 5                                      | 1                                           | 1                             |
| 21   | 51          | 20  | 1G0P              | Abdominal pressure                         | No                    | No                    | 14 × 8 × 7                 | Type 6                                          | 4                                           | 0                             |
| Median | 46          | 21  | -                 | -                                          | -                    | -                      | (1 – 7)                   | (0 – 6)                                        | (1 – 7)                          | (0 – 6)                       |

BMI, body mass index; PALM-COEIN, polyp, adenomyosis, leiomyoma, malignancy and hyperplasia, coagulopathy, ovulatory dysfunction, endometrial, iatrogenic, and not yet classified; GnRHa, gonadotropin-releasing hormone agonist or antagonist; G, gravidity; P, parity; C, cesarean.
feasible, difficult TLH in patients with large cervical fibroids would be made easier by debulking surgery.

Furthermore, as a strategy to reduce the blood loss, we administered diluted vasopressin solution during TLH for large cervical fibroids. Diluted vasopressin solution is generally administered in LM to reduce blood loss. Some studies have also reported that the administration of a diluted vasopressin solution during TAH or vaginal hysterectomy results in a significant reduction in blood loss. However, as bradycardia, cardiac arrest, and other complications have been reported as side effects of vasopressin, patients should be informed about the risks prior to surgery, and diluted vasopressin solution must be used with caution.

In this study, we performed TLH, and not LAVH, to reduce blood loss and complete hysterectomy for large

| Case | LECF or LCA during TLH | Suture after enucleation of fibroids | Uterine Weight (g) | Operative Time (Min) | Estimated Volume of blood loss (mL) | In Bag Morcellation | Histopathologic Findings | Postoperative Hospitalization (Days) |
|------|------------------------|-------------------------------------|--------------------|---------------------|-------------------------------------|-------------------|------------------------|-------------------------------------|
| 1    | -                      | -                                   | 686                | 230                 | 10                                  | Not done          | Leiomyomas and adenomyosis | 5                                   |
| 2    | LECF                   | Yes                                 | 661                | 228                 | 150                                 | Not done          | Leiomyoma               | 5                                   |
| 3    | LECF                   | Yes                                 | 763                | 244                 | 675                                 | Not done          | Leiomyomas and adenomyosis | 4                                   |
| 4    | LCA after LECF         | No                                  | 356                | 165                 | 90                                  | Not done          | Leiomyoma               | 4                                   |
| 5    | LECF                   | No                                  | 362                | 187                 | 100                                 | Not done          | Leiomyomas and adenomyosis | 4                                   |
| 6    | LECF                   | Yes                                 | 980                | 180                 | 150                                 | Not done          | Leiomyoma               | 4                                   |
| 7    | -                      | -                                   | 572                | 147                 | 75                                  | Not done          | Leiomyoma               | 4                                   |
| 8    | LCA before LECF        | No                                  | 894                | 254                 | 300                                 | Not done          | Leiomyoma               | 6                                   |
| 9    | -                      | -                                   | 441                | 158                 | 200                                 | Not done          | Leiomyoma               | 5                                   |
| 10   | LECF                   | No                                  | 318                | 165                 | 50                                  | Not done          | Leiomyoma               | 5                                   |
| 11   | LECF                   | Yes                                 | 831                | 204                 | 280                                 | Not done          | Leiomyoma               | 5                                   |
| 12   | LCA                    | No                                  | 897                | 152                 | 80                                  | Not done          | Leiomyoma               | 4                                   |
| 13   | -                      | -                                   | 609                | 190                 | 50                                  | Not done          | Leiomyoma               | 4                                   |
| 14   | LCA                    | No                                  | 910                | 200                 | 50                                  | Not done          | Leiomyoma               | 4                                   |
| 15   | LCA                    | No                                  | 760                | 230                 | 550                                 | Not done          | Lipoleiomyoma           | 5                                   |
| 16   | LCA                    | No                                  | 844                | 191                 | 100                                 | Not done          | Leiomyoma               | 4                                   |
| 17   | LCA                    | No                                  | 779                | 252                 | 245                                 | Not done          | Leiomyoma               | 5                                   |
| 18   | LCA                    | No                                  | 1502               | 211                 | 110                                 | Not done          | Leiomyoma               | 4                                   |
| 19   | LCA                    | No                                  | 750                | 186                 | 600                                 | Done              | Leiomyoma               | 4                                   |
| 20   | LCA after LECF         | No                                  | 442                | 205                 | 100                                 | Done              | Leiomyoma               | 5                                   |
| 21   | LECF                   | No                                  | 650                | 165                 | 50                                  | Done              | Leiomyomas, adenomyosis and Adenomatoid tumor | 5                                   |

Median (range) 750 (318 – 1502) 191 (147 – 254) 100 (10 – 675) 4 (4 – 6)

LECF, laparoscopic enucleation of large cervical fibroids; LCA, laparoscopic cervical amputation; TLH, total laparoscopic hysterectomy.
cervical fibroids. TLH has been associated with a significant reduction in blood loss when compared to LAVH. And the treatment of the uterine cervical surroundings through the vaginal cavity in LAVH for large cervical fibroids is considered difficult, especially through the narrow vaginal cavity seen in nulliparous patients. Therefore, TLH is probably easier to perform than LAVH for large cervical fibroids.

Using these surgical methods, we could successfully complete TLH for large cervical fibroids. Enucleation, cervical amputation, administration of diluted vasopressin solution, and performing TLH and not LAVH, are generally performed as laparoscopic surgical methods for uterine fibroids, and do not require special instruments or special surgical techniques, such as temporary endovascular balloon occlusion of the bilateral internal iliac arteries, or ureterolysis, transection of the anterior layer of the vesicouterine ligament, and isolation of the ureter. Therefore, when performing TLH for large cervical fibroids, these surgical methods appear easier to generalize, compared to using special instruments or special surgical techniques. To our knowledge, there has been no report of completing TLH for large cervical fibroids without blood transfusion by performing debulking surgery and this is the first report.

In some reports of laparoscopic hysterectomy for cervical fibroids, blood transfusions were performed due to substantial blood loss. In addition, it has been reported that postoperative blood transfusion was necessary in 1 of 12 cases that underwent cervical myomectomy. Therefore, pre-operative preparation for blood transfusion, including autologous blood, was undertaken for some of our cases; however, transfusion was not required. Nevertheless, preparation for blood transfusion appears necessary when performing TLH for large cervical fibroids as a high-level of laparoscopic skill is required.

Of the 21 cases, one ureteral injury occurred (4.8%), and this was the only case of ureteral injury among the 463 patients who underwent TLH during this study period. Therefore, the rate of ureteral injury of these 463 TLH cases was 0.2%, which is similar to that reported by other studies of laparoscopic hysterectomy (0.3 – 0.5%). However, this rate is high, considering that only 21 patients underwent TLH for large cervical fibroids, thereby indicating the difficulty of TLH in such cases. Ureteral injury is one of the most serious complications of total hysterectomy. In order to prevent ureteral injury, insertion of ureteral catheters before operation seems to be the optimal method. However, to our knowledge, there are no reports that the procedure significantly reduces the incidence of ureteral injury during laparoscopic hysterectomy for benign disease. Furthermore, insertion of ureteral catheters requires urologist input, and results in additional time and cost; ureteral catheter insertion also has some complications, such as pain caused by the catheters, hematuria, reflux anuria, and urinary tract infection. On the other hand, the advantage of inserting ureteral catheters is that the ureteral bulge against the peritoneum and the elasticity of the ureteral catheters may allow the path of the ureter to be confirmed, resulting in less severe ureteral injury. Therefore, in cases of TLH for large cervical fibroids, because of poor pelvic visibility and decreased uterine mobility, it is advised that ureteral catheters should be inserted to check the path of the ureter.

Intraoperative cystoscopy is often performed during a hysterectomy to detect lower urinary tract injuries. Although intraoperative cystoscopy does not always detect lower urinary tract injuries, lower urinary tract injuries have been often detected by intraoperative cystoscopy, and this intervention reportedly minimizes long-term sequelae. In addition, intraoperative cystoscopy is easier to perform over ureteral catheter insertion and has a lower risk of complications. We performed intraoperative cystoscopy in all 463 cases of TLH during this study. However, the case of lower urinary tract injury (case 17) was discovered only before cystoscopy.

TLH has been widely performed and has many advantages compared to TAH. However, in the case of TLH for large cervical fibroids, additional expertise and skilled laparoscopic techniques are required to complete the surgery. Therefore, conversion to open surgery is needed when the completion of TLH for large cervical fibroids becomes difficult, even if debulking surgeries is attempted. Moreover, these procedures should never be attempted by a novice surgeon.

**CONCLUSION**

TLH for large cervical fibroids is a minimally invasive surgery. Although it requires a high level of expertise and laparoscopic skill, our data suggests that it is still feasible for large cervical fibroids and can be performed without the need for blood transfusion by performing debulking surgeries, such as enucleation of the fibroids or cervical amputation. A limitation of our study is that we only included 21 women; therefore, further studies with a larger sample size are required to confirm our findings.
References:

1. Tiltman AJ. Leiomyomas of the uterine cervix: a study of frequency. *Int J Gynecol Pathol.* 1998;17(3):231–234.

2. Drinville JS, Memarzadeh S. Benign disorders of the uterine corpus. In: DeCherney AH, Nathan L, eds. *Current Obstetrics and Gynaecologic Diagnosis and Treatment.* New York: Lange-McGraw Hill, 2007:639–653.

3. Monarchghan JM, Lopes T, Naik R. Total hysterectomy for cervical and broad ligament fibroids. In: *Monarchghan JM, Lopes T, Naik R. Bonney’s Gynaecological Surgery.* Oxford: Blackwell Publishing Ltd, 2004:74–86.

4. Hiramatsu Y. Hysterectomy for cervical and intraligamental fibroids. *Surg J (NY).* 2020;6(Suppl 1):S2–S10.

5. Warren L, Ladapo JA, Borah BJ, Gunnarsson CL. Open abdominal versus laparoscopic and vaginal hysterectomy: analysis of a large United States payer measuring quality and cost of care. *J Minim Invasive Gynecol.* 2009;16(5):581–588.

6. Walsh CA, Walsh SR, Tang TY, Slack M. Total abdominal hysterectomy versus total laparoscopic hysterectomy for benign disease: a meta-analysis. *Eur J Obstet Gynecol Reprod Biol.* 2009;144(1):3–7.

7. Takeda A, Koyama K, Imoto S, Mori M, Nakano T, Nakamura H. Temporary endovascular balloon occlusion of the bilateral internal iliac arteries to control hemorrhage during laparoscopic-assisted vaginal hysterectomy for cervical myoma. *Eur J Obstet Gynecol Reprod Biol.* 2011;158(2):319–324.

8. Nakayama K, Tsukao M, Ishikawa M, et al. Total laparoscopic hysterectomy for large uterine cervical fibroid. *Mol Clin Oncol.* 2017;6(5):655–660.

9. Taniguchi F, Koike N, Kikukawa T, et al. An evaluation of laparoscopic hysterectomy alone versus in combination with laparoscopic myomectomy for patients with uterine fibroids. *Eur J Obstet Gynecol Reprod Biol.* 2017;210:132–138.

10. Sinha R, Sundaram M, Lakhota S, Hegde A. Cervical myomectomy with uterine artery ligation at its origin. *J Minim Invasive Gynecol.* 2009;16(5):604–608.

11. Matsuoka S, Kikuchi I, Kitade M, et al. Strategy for laparoscopic cervical myomectomy. *J Minim Invasive Gynecol.* 2010;17(3):301–305.

12. Chang WC, Chen SY, Huang SC, Chang DY, Chou LY, Sheu BC. Strategy of cervical myomectomy under laparoscopy. *Fertil Steril.* 2010;94(7):2710–2715.

13. Nimarrick ML, Dimino M, Maloney S. Laparoscopic-assisted vaginal hysterectomy of large myomatous uteri with supracervical amputation followed by trachelectomy. *J Am Assoc Gynecol Laparosc.* 1996;3(4):585–587.

14. Yen YK, Liu WM, Yuan CC, Ng HT. Comparison of two procedures for laparoscopic-assisted vaginal hysterectomy of large myomatous uteri. *J Am Assoc Gynecol Laparosc.* 2002;9(1):63–69.

15. Munro MG, Critchley HO, Broder MS, Fraser IS. FIGO classification system (PALM-COEIN) for causes of abnormal uterine bleeding in nongravid women of reproductive age. *Int J Gynaecol Obstet.* 2011;113(1):3–13.

16. Okin CR, Guido RS, Meyn LA, Ramanathan S. Vasopressin during abdominal hysterectomy: a randomized controlled trial. *Obstet Gynecol.* 2001;97(6):867–872.

17. Ascher-Walsh CJ, Capes T, Smith J, Michels A. Cervical vasopressin compared with no premedication and blood loss during vaginal hysterectomy: a randomized controlled trial. *Obstet Gynecol.* 2009;113(2 Pt 1):313–318.

18. Rimbach S, Schempersheofe M. In-Bag morcellation as a routine for laparoscopic hysterectomy. *Biomed Res Int.* 2017;2017(3):6701916.

19. O’Hanlan KA. Cystoscopy with a 5-mm laparoscope and suction irrigator. *J Minim Invasive Gynecol.* 2007;14(2):260–263.

20. Dindo D, Demartines N, Clavien PA. Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. *Ann Surg.* 2004;240(2):205–213.

21. Protopapas A, Giannoulis G, Chatzipapas I, et al. Vasopressin during laparoscopic myomectomy: does it really extend its limits? *J Minim Invasive Gynecol.* 2019;26(3):441–449.

22. Hobo R, Netsu S, Koyasu Y, Tsutsumi O. Bradycardia and cardiac arrest caused by intramyometrial injection of vasopressin during a laparoscopically assisted myomectomy. *Obstet Gynecol.* 2009;113(2 Pt 2):484–486.

23. Tulandi T, Béique F, Kimia M. Pulmonary edema: a complication of local injection of vasopressin at laparoscopy. *Fertil Steril.* 1996;66(3):478–480.

24. Sesti F, Così V, Calonzi F, et al. Randomized comparison of total laparoscopic, laparoscopically assisted vaginal and vaginal hysterectomies for myomatous uteri. *Arch Gynecol Obstet.* 2014;290(3):485–491.

25. Drahonovsky J, Haakova L, Otcenasek M, Krofta L, Kucera E, Feyereisl J. A prospective randomized comparison of vaginal hysterectomy, laparoscopically assisted vaginal hysterectomy, and total laparoscopic hysterectomy in women with benign uterine disease. *Eur J Obstet Gynecol Reprod Biol.* 2010;148(2):172–176.

26. Brummer TH, Jalkanen J, Fraser J, et al. FINHYST, a prospective study of 5279 hysterectomies: complications and their risk factors. *Hum Reprod.* 2011;26(7):1741–1751.

27. Propst K, Harnegay MP, Ridgeway B. Evaluation of strategies to prevent urinary tract injury in minimally invasive
gynecologic surgery: a systematic review. *J Minim Invasive Gynecol.* 2021;28(3):684–691. Epub 2020 Jul 27.

28. Tanaka Y, Asada H, Kuji N, Yoshimura Y. Ureteral catheter placement for prevention of ureteral injury during laparoscopic hysterectomy. *J Obstet Gynaecol Res.* 2008;34(1):67–72.

29. Chou M-T, Wang C-J, Lien R-C. Prophylactic ureteral catheterization in gynecologic surgery: a 12-year randomized trial in a community hospital. *Int Urogynecol J Pelvic Floor Dysfunct.* 2009;20(6):689–693.

30. Jelovsek JE, Chiung C, Chen G, Roberts SL, Paraiso MF, Falcone T. Incidence of lower urinary tract injury at the time of total laparoscopic hysterectomy. *JSLS* 2007;11(4):422–427.